Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors.


Journal

Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805

Informations de publication

Date de publication:
12 2019
Historique:
received: 28 06 2019
revised: 02 10 2019
accepted: 07 10 2019
pubmed: 28 10 2019
medline: 2 9 2020
entrez: 27 10 2019
Statut: ppublish

Résumé

In the ITALUNG lung cancer screening trial after 9.3 years of follow-up we observed an unexpected significant decrease of cardiovascular (CV) mortality in subjects invited for low-dose CT (LDCT) screening as compared to controls undergoing usual care. Herein we extended the mortality follow-up and analyzed the potential factors underlying such a decrease. The following factors were assessed in screenes and controls: burden of CV disease at baseline, changes in smoking habits, use of CV drugs and frequency of planned vascular procedures after randomisation. Moreover, in the screenes we evaluated inclusion of presence of coronary artery calcification (CAC) in the LDCT report form that was transmitted to the participant and his/her General Practitioner. The 2-years extension of follow-up confirmed a significant decrease of CV mortality in the subjects of the active group compared to control subjects (15.6 vs 34.0 per 10,000; p = 0.001) that was not observed in the drops-out of the active group. None of the explaining factors we considered significantly differed between active and control group. However, the subjects of the active group with reported CAC experienced a not significantly lower CV mortality and showed a significantly higher use of CV drugs and frequency of planned vascular procedures than the control group. LDCT screening for lung cancer offers the opportunity for detection of CAC that is an important CV risk factor. Although the underlying mechanisms are not clear, our results suggest that the inclusion of information about CAC presence in the LDCT report may represent a candidate factor to explain the decreased CV mortality observed in screened subjects of the ITALUNG trial, possibly resulting in intervention for patient care to prevent CV deaths. Further studies investigating whether prospective reporting and rating of CAC have independent impact on such interventions and CV mortality are worthy.

Identifiants

pubmed: 31654837
pii: S0169-5002(19)30676-2
doi: 10.1016/j.lungcan.2019.10.006
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02777996']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

72-78

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Donella Puliti (D)

Clinical Epidemiology Unit, ISPRO - Oncological Network, Prevention and Research Institute, Florence, Italy. Electronic address: d.puliti@ispro.toscana.it.

Mario Mascalchi (M)

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Italy. Electronic address: m.mascalchi@dfc.unifi.it.

Francesca Maria Carozzi (FM)

Regional Prevention Laboratory Unit, ISPRO - Oncological Network, Prevention and Research Institute, Florence, Italy. Electronic address: f.carozzi@ispro.toscana.it.

Laura Carrozzi (L)

Cardiothoracic and Vascular Department, University Hospital of Pisa, Italy; Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Italy. Electronic address: laura.carrozzi@unipi.it.

Fabio Falaschi (F)

Radiology Department, University Hospital of Pisa, Italy. Electronic address: f.falaschi@ao-pisa.toscana.it.

Eugenio Paci (E)

Clinical Epidemiology Unit, ISPRO - Oncological Network, Prevention and Research Institute, Florence, Italy. Electronic address: paci.eugenio@gmail.com.

Andrea Lopes Pegna (A)

Pneumonology Department, Careggi Hospital, Florence, Italy. Electronic address: a.lopespegna@gmail.com.

Ferruccio Aquilini (F)

Cardiothoracic and Vascular Department, University Hospital of Pisa, Italy. Electronic address: f.aquilini@ao-pisa.toscana.it.

Alessandro Barchielli (A)

Clinical Epidemiology Unit, ISPRO - Oncological Network, Prevention and Research Institute, Florence, Italy. Electronic address: abarchielli@virgilio.it.

Maurizio Bartolucci (M)

Radiology Department, Careggi Hospital, Florence, Italy. Electronic address: mauriziobartolucci1@gmail.com.

Michela Grazzini (M)

Pneumonology Department, Hospital of Pistoia, Italy. Electronic address: mgrazzini@yahoo.com.

Giulia Picozzi (G)

Radiodiagnostic Unit, ISPRO - Oncological Network, Prevention and Research Institute, Florence, Italy. Electronic address: g.picozzi@ispro.toscana.it.

Francesco Pistelli (F)

Cardiothoracic and Vascular Department, University Hospital of Pisa, Italy. Electronic address: f.pistelli@ao-pisa.toscana.it.

Alessandro Rosselli (A)

Tuscan Regional Health Agency, Florence, Italy. Electronic address: ale.rosselli1@gmail.com.

Marco Zappa (M)

Clinical Epidemiology Unit, ISPRO - Oncological Network, Prevention and Research Institute, Florence, Italy. Electronic address: m.zappa@ispro.toscana.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH